Despite their association with CRC progression and metastasis, studies on the prognostic effect of EREG and AREG expression on survival are limited by a lack of treatment naïve patients, such that biomarker-treatment interactions cannot be excluded. This evidence concerns the gene AREG and colorectal carcinoma.